ET Pharma

Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says

Sep 21, 2026, 1:00 PM

Translate article text

Choose a language and wait for the translated text.

The company is racing to reassure markets that it can navigate patent expirations for semaglutide - the active ingredient in its anti-obesity drugs Ozempic and Wegovy franchises - in the early 2030s.